Meeting on the Med 2022 | Assessing PDC*mel, dendritic cell-based vaccine in melanoma

Eric Halioua, PDC*line Pharma, Liege, Belgium, discusses the development of PDC*mel, a plasmacytoid dendritic cell (PDC)-derived vaccine for patients with melanoma. The investigational therapy consists of PDC*line loaded with four melanoma peptides and have the ability to be stored in liquid nitrogen. He also describes a Phase I trial (NCT01863108), which tested the vaccine in three different doses. This interview was conducted during Meeting on the Mediterranean 2022.